

Mourad Sanhaji

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1533936/publications.pdf>

Version: 2024-02-01

14
papers

383
citations

840776

11
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

736
citing authors

#	ARTICLE	IF	CITATIONS
1	Cdk1/Cyclin B1 Controls Fas-Mediated Apoptosis by Regulating Caspase-8 Activity. <i>Molecular and Cellular Biology</i> , 2010, 30, 5726-5740.	2.3	80
2	Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1. <i>Molecular Oncology</i> , 2015, 9, 140-154.	4.6	47
3	PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells. <i>Nature Communications</i> , 2018, 9, 1106.	12.8	47
4	Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8. <i>Cell Research</i> , 2016, 26, 914-934.	12.0	35
5	Boosting the apoptotic response of high-grade serous ovarian cancers with <i>CCNE1</i> amplification to paclitaxel <i>in vitro</i> by targeting APC/C and the pro-survival protein MCL1. <i>International Journal of Cancer</i> , 2020, 146, 1086-1098.	5.1	29
6	Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8142-8160.	6.4	28
7	Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability. <i>Neoplasia</i> , 2019, 21, 363-375.	5.3	27
8	Synthetic lethality in <i>CCNE1</i> -amplified high grade serous ovarian cancer through combined inhibition of Polo-like kinase 1 and microtubule dynamics. <i>Oncotarget</i> , 2018, 9, 25842-25859.	1.8	24
9	The Small-Molecule Inhibitor MR1A9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells. <i>Cancers</i> , 2021, 13, 3658.	3.7	17
10	The Prognostic Relevance of the Proliferation Markers Ki-67 and Plk1 in Early-Stage Ovarian Cancer Patients With Serous, Low-Grade Carcinoma Based on mRNA and Protein Expression. <i>Frontiers in Oncology</i> , 2020, 10, 558932.	2.8	15
11	Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds. <i>ACS Chemical Biology</i> , 2018, 13, 1921-1931.	3.4	12
12	A dimerization-dependent mechanism regulates enzymatic activation and nuclear entry of PLK1. <i>Oncogene</i> , 2022, 41, 372-386.	5.9	10
13	The Role of DAPK1 in the Cell Cycle Regulation of Cervical Cancer Cells and in Response to Topotecan. <i>Journal of Cancer</i> , 2022, 13, 728-743.	2.5	7
14	The role of PLK1 in cancer exhibiting chromosomal instability. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1485539.	0.7	4